Unilever PLC (NYSE: UL) — Cutting Itself Down to a Premium, Still Priced as a Conglomerate

Independent equity research. Report date: 2026-06-27. ADR ~$60.55 (1 ADR = 1 ordinary share; primary listing London ULVR.L / Amsterdam). Reporting currency EUR; FY = calendar year.

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice and not a recommendation to buy or sell any security. The analysis that follows takes no position, carries no price target, and discusses valuation only as embedded expectations and scenarios.

Verdict: HOLD / quality-at-a-discount — accumulate on weakness in the low-to-mid $50s, not at $60+. Not a short. Medium conviction. Directional value zone: the ADR is roughly fair-to-slightly-rich at ~$60 on the correct earnings base (~17–18x underlying EPS, ~14.4x EV/EBITDA); the asymmetry only turns attractive in the ~$50–55 area (≈13x EV/EBITDA / ≈15x underlying earnings), where the market would be handing you the post-surgery RemainCo and the McCormick stake for the price of the legacy conglomerate. A reasonable fair-value zone if the two-step transformation lands and re-rates modestly toward P&G is ~$70–82; the bear floor on a stalled turnaround is ~$50–54 (where it traded in April 2026).

The framing is contrarian quality-at-a-discount, not deep value and not a falling knife. The single most important thing to understand about UL is that the headline ~11x P/E is a mirage — it divides the price by a GAAP EPS (€4.34) that is inflated by a one-off ~€3.8bn gain on the December-2025 Ice-Cream (Magnum) demerger. On the company’s own underlying EPS of €3.08, this is a ~17–18x stock: a normal ~20–25% quality-gap discount to P&G, not the dramatic half-price the screen implies. Anyone buying “UL at 11x, half of P&G” is buying a demerger artifact. What you are buying is a genuinely second-tier-but-improving staples franchise mid-way through self-amputation: Ice Cream is gone, Foods goes to McCormick in a $44.8bn tax-efficient Reverse Morris Trust (announced 31-Mar-2026, closing mid-2027), and what remains is a focused ~$40–44bn Beauty/Wellbeing/Personal Care/Home Care pure-play at ~20%+ underlying margin — a portfolio that arguably deserves a premium-beauty multiple it does not yet get. The market is paying for UL’s algorithm (mid-single-digit growth, ~20% margin) and giving zero credit for the transformation. The factor tape agrees it is un-loved: beta 0.12, strongly defensive (BetaFactor −0.46, LowVol +0.24), no momentum and no value loading, five years of dead money (+1.2%/yr, Sharpe −0.04), but a recent +12% (annualized) three-month inflection — abandoned, not collapsing.

Why only a HOLD, and why medium conviction. Three things keep me from getting excited at $60: (1) ROIC has drifted down from 17.4% (FY19) to ~14% (FY25) despite a full +670bp gross-margin recovery — a Marathon red flag that a decade of goodwill-heavy premium-beauty M&A has been adding capital below the legacy return; (2) UL has promised re-acceleration for the better part of a decade and FY25 USG of 3.5% still undershot its own mid-single-digit floor, with FY26 guided only to ~4%; and (3) the transformation hands shareholders McCormick stock, not clean cash — the outcome is now partly hostage to MKC’s execution and multiple, and the $15.7bn cash must be redeployed well by a team whose prior big swings (Dollar Shave Club, the £50bn GSK bid) were the textbook mistakes. Tag: “two amputations from a re-rate the market won’t pre-pay for.”

Conviction: medium. The single piece of evidence that flips me bullish: RemainCo sustaining 4%+ underlying sales growth with positive volume through the Foods close, with the multiple still stuck at ~14x — that is the mispriced transformation. The single piece that flips me bearish: USG sliding back to 2–3% with flat/negative volume, or a large, richly-priced premium-beauty acquisition (a “GSK redux”) that confirms the ROIC drift is structural. Until one or the other prints, this is a fairly-priced, defensively-attractive compounder to own cheaper, not here.

📈 Stock Price Action — Five-Year Event Map

Factual price history, not a recommendation. Price moves are FACT; attributed causes are INTERPRETATION. No price target, no chart levels.

Over the trailing ~60 months the UL ADR went almost nowhere, then finally inflected. It traded a ~$50 “dead-money” handle through 2019–2023, bottomed at $42.44 (2022-05-19), and only broke out durably in 2024–25 as the Growth Action Plan turnaround and the portfolio break-up took hold — closing 2024 at ~$60.77 and 2025 at ~$64.28, then spiking to a five-year high of $73.31 (2026-02-13) around FY25 results and the completed Ice-Cream demerger. It has since pulled back to ~$60.55, roughly −17% off the February high, back to the level it first reached at end-2024. The five-year annualized price return is ~+1.2% (Sharpe ~−0.04) — dead money that has only recently shown a pulse. 52-week range ~$55–$73.

Cycle narrative. (1–2) UL’s rejected £50bn pursuit of GSK’s consumer-health arm in January 2022 was read as exactly the value-destroying empire-building the bear case fears; the stock fell ~15% in days and ground to its $42.44 low in May as input inflation simultaneously crushed margins. (3) Trian (Peltz) took a board seat in mid-2022 and Schumacher arrived in 2023, but the price stayed near $50 as growth was carried by pricing while volumes were negative — the textbook sub-peer-grower setup that earned UL its discount. (4) The Growth Action Plan and the March-2024 decision to demerge Ice Cream drove a ~24% re-rate — the first evidence the re-acceleration promise might finally be real. (5) A steadier 2025 grind as USG stayed positive with returning volume, €800m of productivity landed, Fernandez took over, and Ice Cream spun off in December (step one of the break-up). (6) FY25 results plus a clean “focused RemainCo” story and buyback carried the ADR to its $73.31 five-year high in February 2026. (7) The 31-March-2026 Foods → McCormick announcement crystallized step two of the break-up, but the stock has since given back ~17% as the market digests what RemainCo actually is, takes profit, and re-applies a staples/EM-FX discount.

1. Executive Summary

Unilever PLC is one of the three or four largest fast-moving consumer-goods (FMCG) companies on earth — €50.5bn of FY2025 turnover across ~190 countries, anchored by 30 “Power Brands” (Dove, Hellmann’s, Knorr, Rexona, Vaseline, OMO, Liquid I.V.) that produce ~78% of sales, with the highest emerging-market weighting (~59%) of the staples majors. It is a genuinely cash-generative, asset-light franchise — gross margin 46.9%, underlying operating margin 20.0%, capex ~3.2% of sales, FCF ~€5.9–6.8bn, a negative cash-conversion cycle, ~3% dividend yield with a steady ~€1.5bn/yr buyback. The moat is real: brand-intangible/habit captivity, advertising/distribution/procurement scale, and a genuinely differentiated emerging-market route-to-market.

But it is a second-tier operator within a good industry. Unilever earns ~5 points less operating margin than P&G (~25%), roughly half Colgate’s ROIC (~33%), and below Reckitt’s adjusted operating margin (~25%). Its computed ROIC (~14%, with goodwill) has drifted down from 17.4% in FY19 despite a full margin recovery — the signature of a serial acquirer adding goodwill-heavy capital below its legacy return. Growth has been chronically sub-peer: for three of the last five years (2022–23 most acutely) “growth” was inflation pass-through accompanied by volume loss. Volume genuinely returned in 2024–25, but FY25 USG of 3.5% still undershot the company’s own mid-single-digit floor, and FY26 is guided only to ~4%.

The investable angle is a two-step portfolio transformation, not the headline cheapness. Unilever is amputating its two lowest-quality legs: Ice Cream was demerged in December 2025 (The Magnum Ice Cream Company), and Foods is being combined with McCormick in a $44.8bn Reverse Morris Trust announced 31-March-2026 (McCormick pays $15.7bn cash + ~$29.1bn stock; UL holders end up owning ~55.1% of the combined ~$20bn-revenue McCormick, Unilever retains ~9.9%; tax-efficient; closes mid-2027). What remains is a focused ~$40–44bn Beauty/Wellbeing/Personal Care/Home Care company at ~20%+ underlying margin — a higher-quality, higher-growth portfolio that could re-rate toward premium-beauty peers, plus $15.7bn of redeployable cash. Governance is above-average for the change: an independent chair, an aligned activist (Peltz/Trian) on the board, and underlying ROIC weighted 30% in the long-term incentive plan — directly targeting the return-drift problem.

The crux, on the right earnings base: strip the demerger gain and Unilever trades at ~17–18x underlying EPS (€3.08) and ~14.4x EV/EBITDA — the low end of its own 10-year band and a modest discount to P&G, not a deep-value bargain. The market prices the algorithm and gives no credit for a successful re-rating. That makes UL a defensible, low-beta, quality-at-a-discount holding with genuine transformation optionality — but one whose risk/reward is far more attractive a few dollars lower than at $60, given a decade of broken promises, an EM-FX drag that recurs every year, and the fact that shareholders are being handed acquirer stock rather than clean cash.

No recommendation and no price target appear in this body; the single labeled exception is Claude’s Take above.

2. Business Overview

What Unilever is. Unilever PLC is a London-headquartered, EUR-reporting branded-FMCG manufacturer that sold €50,503m of turnover in FY2025 [FACT — aggregated data; FY25 results] across ~190 countries, reaching, on its own claim, ~3.4 billion consumers a day. It makes daily-use, low-ticket, repeat-purchase products — deodorant, soap, shampoo, skin cream, laundry detergent, household cleaner, mayonnaise, bouillon, hydration powders — under a portfolio anchored by 30 “Power Brands” that generate ~78% of turnover [FACT — FY25 results, 12-Feb-2026]. The model is the classic branded-FMCG royalty: build brand equity with very large absolute advertising spend (~€8–9bn brand-and-marketing investment, ~€1bn R&D), manufacture and distribute at low unit cost via global scale, and earn a recurring, habit-driven (not contractual) revenue stream at a price premium to private label.

The four segments (post Ice-Cream demerger). Through FY2024 Unilever reported five Business Groups; in December 2025 it demerged Ice Cream (Magnum, Wall’s, Ben & Jerry’s, Cornetto) into The Magnum Ice Cream Company, removing its lowest-margin, most-seasonal, most-capital-intensive division. The continuing business is now four Business Groups (FY2025 turnover / underlying operating margin / USG):

[FACT — FY25 segment turnover/margins/USG, Unilever FY2025 Full Year Results, 12-Feb-2026.] Personal Care and Beauty & Wellbeing are the premium growth engines — they grew underlying sales +4.7% and +4.3% with healthy volume, and Personal Care carries the best margin (22.6%). Home Care is the lowest-quality leg — 14.9% margin, growth almost entirely volume with near-zero pricing (+0.4%), most exposed to commodity (surfactant/petrochemical) input swings and EM-FX. Foods is the anomaly: a record 22.6% margin but the slowest grower (+2.5%, volume only +0.8%) — and the segment Unilever is now exiting.

Key brands. Personal Care / Beauty: Dove (the ~$10bn-plus flagship spanning soap, body wash, deodorant, hair), Rexona/Sure/Degree (deodorant), Axe, Vaseline, Pond’s, Sunsilk/TRESemmé/Nexxus/Clear (hair), Lux, Lifebuoy (hygiene soap, huge in South Asia), plus premium/Prestige and “Wellbeing” acquisitions — Dermalogica, Paula’s Choice, K18, Hourglass, Tatcha and Liquid I.V., Nutrafol, OLLY, SmartyPants, and the 2025-acquired Dr. Squatch. Home Care: OMO/Persil, Surf (laundry), Comfort (fabric conditioner), Domestos (bleach), Cif (surface cleaner). Foods: Hellmann’s (mayonnaise), Knorr (UL’s largest single brand), Marmite, Maille, Unilever Food Solutions (B2B). [FACT — company profile (aggregated data); FY25 reporting.]

Geographic mix. Emerging markets are ~59% of turnover [FACT — FY25 results] — a structurally higher EM weighting than P&G, Colgate or Nestlé. India (Hindustan Unilever, a separately-listed ~62%-owned subsidiary), Brazil, Indonesia, China, Turkey, South Africa and the Philippines are core. This is the single biggest structural differentiator versus developed-market-tilted peers: more long-run penetration runway, but more FX translation drag (FY2025 turnover fell −3.8% reported despite +3.5% underlying and +2.3% constant-currency, the gap being currency) and more political/macro risk.

Business model & recurring nature. Branded FMCG is a “scale + distribution + marketing” royalty. Unilever does not own the consumer relationship contractually; it owns brand preference — the reflexive reach for Dove or Knorr at the shelf. Revenue is recurring in the consumption sense (short re-buy cycles) but not subscription. Capital intensity is low (capex ~3.2% of sales, FCF ~€5.9–6.8bn) — an asset-light, cash-generative compounder, though, as argues, a second-tier one.

Strategy under new management. CEO Fernando Fernandez (CFO promoted to CEO March 2025, replacing Hein Schumacher after ~18 months) runs the Growth Action Plan / GAP2030: concentrate investment on the 30 Power Brands, fewer-bigger-better innovation, faster route-to-market, and a Productivity Programme targeting ~€800m of savings (~7,500 office roles). The portfolio is being actively reshaped toward higher-growth, higher-margin Beauty & Personal Care: Ice Cream demerged (Dec-2025); Foods combining into McCormick (Mar-2026, ); premium bolt-ons added (Dr. Squatch, K18, Minimalist, Nutrafol); local-foods tails divested (Graze, Unox, Conimex).

Verdict (Business Overview). A genuinely global, scaled, recurring-demand branded-FMCG business with one of the deepest brand portfolios in the world and the highest EM exposure of the staples majors, transforming into a more focused Beauty & Personal Care + Home Care company. The business model is structurally good; the open question is whether Unilever executes it to P&G’s standard or merely owns breadth.

3. Industry Dynamics

Unilever competes in the global household & personal care (HPC) and packaged-foods industries — mature, consolidated, low-growth, defensive oligopolies with attractive economics for the scaled leaders and brutal economics for the unscaled. The appeal is durability, not dynamism.

Market size, growth and profit pools. The relevant global HPC categories run to several hundred billion dollars and grow only low-single-digits in value (~2–4%), well below the 2021–23 pricing surge. Packaged foods grow even more slowly, with volume often flat-to-negative in developed markets. This is the central industry fact: the pie barely grows, so returns depend on share gains, premiumization/mix, productivity and capital return, not a rising tide. The profit pool is concentrated among a handful of scaled multinationals competing against each other and against retailers’ private label.

Competitive set and intensity. Unilever’s competitors differ by category — and that breadth is itself a feature and a weakness (a focused rival beats a generalist in any single category):

[FACT — peer margins from FY2025 filings/results and public PG/CL filings.] Competitive intensity is moderate and largely rational in core HPC categories — incumbents compete on innovation and advertising more than destructive price — but two structural pressures stand: (1) private label, strongest in developed-market home care, laundry and parts of foods, which gains share in down-traded moments (a live threat into the 2024–25 cost-of-living squeeze); and (2) local / digitally-native challengers — VC-funded DTC brands in deodorant, skincare, hair and “clean” personal care that erode share at the category edge (Unilever’s response has been to acquire them: Dr. Squatch, Liquid I.V., Nutrafol, Paula’s Choice). In emerging markets, local players (Godrej, Marico in India; Natura in Brazil) are tougher, lower-cost competitors than the global majors.

Emerging-market structural growth + FX. The defining feature of UL’s exposure is its ~59% EM weighting. EM provides the genuine secular growth in an otherwise flat industry — rising incomes, formalization, premiumization, per-capita catch-up. But it imports persistent currency drag (the −3.8% reported / +2.3% constant-currency / +3.5% underlying FY2025 gap is almost entirely FX), translation volatility, and macro/political risk (Argentina, Turkey, Nigeria devaluations; India regulatory). A double-edged attribute: more growth, but lower-quality (FX-eroded, more volatile) growth than a developed-market staples book.

Retailer power and value chain. Commodity input suppliers → branded manufacturers (Unilever et al.) → retailers → consumers. Unilever sits in the powerful-but-squeezed middle: upstream, input costs (palm oil, surfactants/petrochemicals, packaging, edible oils for Foods) are commoditized and volatile — the post-COVID 2021–23 input-cost cycle drove gross margin to ~40% in FY2022 before pricing recovered it to ~47% by FY2025 [FACT — aggregated data]. Downstream, retailer concentration (Walmart, Tesco, Carrefour, Amazon, plus hard discounters Aldi/Lidl who push private label) holds real bargaining power and disciplines branded pricing. The branded manufacturer captures the largest, most stable slice of the chain’s profit (hence ~47% gross margins vs. thin-margin retailers) — but that slice is perpetually contested from both ends.

Regulation. Light relative to pharma/banking — product safety, advertising claims, packaging/plastics, and (in Foods) labeling/HFSS rules — not a thesis driver, though plastics/sustainability regulation and EM price controls are watch-items.

Capital cycle (Marathon lens). HPC/Foods is a low-asset-growth, high-return, supply-disciplined industry — capital does not flood in and mean-revert returns the way it does in cyclicals, because brand/scale barriers suppress the supply response; there is no classic capacity-glut anomaly here. The Marathon framework instead points to where the threat lives: not the supply side (disciplined by barriers) but the demand side (a tapped-out consumer capping pricing) and value-chain capture by retailers/private label. The one place capital does periodically flood is VC-funded DTC challengers and the premium-beauty M&A land-grab (the 2017–24 scramble for prestige skin/wellbeing assets, where buyers paid full multiples for high-apparent-return assets that then mean-revert). Unilever’s own serial bolt-ons sit squarely in this dynamic — a Marathon caution on capital allocation, not on industry structure.

Verdict (Industry): structurally GOOD for the scaled leader — durable, defensive, high-barrier, rationally supplied — but mature, low-growth, and FX/private-label-pressured. Unilever’s specific exposure is a higher-growth but lower-quality version of the staples industry: more EM secular runway, but more currency drag, more local competition, and a Foods leg whose slow growth it is now jettisoning. The industry is good; Unilever’s position within it is the real question.

4. Competitive Position

Name the moat (Greenwald taxonomy). Unilever’s competitive advantage is real but second-tier, resting on three mechanisms, in descending order of strength:

1. Brand intangibles / customer captivity (habit). The dominant moat in daily-use staples is reflexive repeat purchase: a consumer who buys Dove, Rexona, Knorr or OMO reaches for it without deliberation; the product is cheap relative to the cost of a bad outcome, so the consumer is price-tolerant and switching-averse. This captivity is product-specific, not portfolio-wide — it protects Dove deodorant, not “Unilever” — and is strongest in the 30 Power Brands (78% of turnover), weakest in the long tail UL is pruning.
2. Economies of scale in advertising, distribution and procurement. A ~€50bn revenue base supports ~€8–9bn of absolute brand-and-marketing spend and one of the deepest global supply chains, amortized over the largest volume base — a classic Greenwald economies-of-scale advantage. A sub-scale competitor spending the same percentage of sales spends a fraction of the dollars and cannot match UL’s media reach or innovation cadence.
3. Emerging-market distribution density / route-to-market. Unilever’s most differentiated asset versus developed-market-tilted P&G/Colgate is its physical distribution reach in emerging markets — getting product into millions of tiny kirana stores, wet markets and informal outlets across India, Indonesia, Africa and Latin America. This is genuinely hard to replicate market-by-market and is the closest thing UL has to a durable, local scale advantage.

Crucially, consumer switching costs are near-zero — no contract, no lock-in, no network effect. The moat is demand captivity by habit reinforced by scale economics, not switching costs or network effects. Any “network effect” claim would be false here.

Does the moat show up in financial outcomes? Partly — and that is the verdict. Greenwald tests:

• ROIC: Unilever earns ~14.3% computed ROIC (FY25), stable ~14–17% FY2019–25 but drifting down (17.4% FY19 → 14.3% FY25) [FACT — aggregated data]. That clears its ~7–8% WACC by a wide margin and confirms a genuine advantage exists — but the downward drift is a Marathon caution that returns are compressing, not compounding. (The company reports a higher underlying ROIC of ~19% on its own ex-goodwill-style definition, which it uses in pay; the standard goodwill-inclusive measure is ~14%. Both are referenced where relevant.)
• Gross margin ~47%, underlying operating margin 20.0% — high in absolute terms, evidence of pricing power and scale, recovered from the 40% FY22 trough.
• Pricing power: demonstrably present — FY2025 underlying growth +3.5% with +2.0% price; Personal Care took +3.6% price; the 2021–23 inflation was passed through and gross margin recovered. (The exception is Home Care: only +0.4% price — the weakest-moat leg.)

The direct quality gap vs. P&G, Colgate, Nestlé, Reckitt — Unilever is the structurally inferior operator within a good industry:

[FACT — UL FY25 from aggregated data + results; peers from FY25 filings/results and public PG/CL filings.] The read is unambiguous on margin and return quality: Unilever sits below P&G on operating margin (~20% vs ~25%) and ROIC (~14% vs ~16%), and far below Colgate (~33% ROIC, ~60% GM) and Reckitt (~25% op margin). P&G earns ~5 points more operating margin and ~2 points more ROIC on a comparable base; Colgate earns more than twice UL’s ROIC. The structural reasons: (a) portfolio breadth without focus — UL spreads across beauty, personal care, home care and foods, where P&G deliberately exited foods/beverages to compete only where superiority earns a premium; (b) the Foods drag (now being divested); © the Home Care drag (14.9% margin, near-zero pricing); (d) EM-FX headwinds; and (e) a long history of operational underperformance — UL repeatedly missed its own 3–5% growth ambition through 2019–23, attracted Trian (2022), botched the £50bn GSK bid (2022), churned CEOs (Polman→Jope→Schumacher→Fernandez), and is demerging Ice Cream / divesting Foods precisely because the conglomerate breadth diluted returns.

The bull rebuttal — a cheap-quality compounder turning? The honest counter: UL’s underlying growth (+3.5%) is faster than P&G’s (~2%) and Colgate’s (~1–2%) right now, with healthy volume (+1.5%); the higher-margin Beauty & Personal Care core is being concentrated; margins are expanding (+60bps group); the Ice-Cream demerger and McCormick-Foods combination strip the two lowest-quality legs; and GAP2030 / €800m productivity are credible self-help. If GAP2030 delivers, UL re-rates from “second-tier conglomerate” toward “focused BPC compounder,” and it already trades at a discount that prices in the inferiority. That is a real, defensible variant view. But it is a hypothesis pending delivery: Unilever has promised re-acceleration for a decade and under-delivered; the ROIC trend is down, not up; and the moat, while real, is structurally narrower than P&G’s (more habit/EM-distribution, less innovation-anchored superiority) and lower-return than Colgate’s concentrated oral-care franchise.

Verdict (Competitive Position): a DURABLE but SECOND-TIER moat. Real brand-intangible and scale advantages, genuinely differentiated EM distribution density, financially proven by ~14% ROIC and ~47% gross margins that would deteriorate without it — but a structurally INFERIOR operator within a good industry, earning ~5 points less operating margin and roughly half Colgate’s ROIC, dragged by portfolio breadth, a low-margin Home Care leg, the (now-exiting) Foods leg, and chronic EM-FX headwinds, against a decade of operational under-delivery. The franchise is too good to be a value trap; the question for the thesis is whether the new focus finally closes the quality gap toward P&G — or whether this is, again, me-too breadth that owns a great industry without earning great-industry returns. On the evidence to date, a good-but-not-great franchise priced for what it is, with the GAP2030 re-rating as the upside option and “another decade of promises” as the bear risk.

5. Growth History and Forward Opportunities

The headline: a serial sub-peer grower whose growth has been mostly inflation. Underlying sales growth (USG), volume vs. price, by year:

[Sources: Unilever FY2021–FY2025 results; FY25 Full Year Results, 12-Feb-2026. Accessed 2026-06-27.] The central growth question, answered: the 2021–23 “growth” was overwhelmingly price/inflation — in 2022 UL printed 9.0% USG while volumes fell 2.1% and price rose 11.3%; in 2023, 7.0% USG was again almost entirely price. That is not demand-driven growth; it is a price-taker passing through commodity inflation and losing units while doing so. The genuine inflection is 2024 (volume +2.9%, first time in years volume led) and 2025 (volume +1.5%). So volume has returned — but it returned weaker in 2025 than 2024, FY25 USG of 3.5% sits below Unilever’s own 3–4% floor, and below the mid-single-digit prints L’Oréal and (historically) Nestlé/P&G have delivered. Unilever has, for the better part of a decade, grown its top line slower than the best of its peers — the durable, uncomfortable fact the bull case must overcome.

Sequential improvement within FY25. Management stressed a “clear sequential improvement,” with Q4 USG of 4.2% (volume 2.1%, price 2.0%) — the strongest quarter [FACT — FY25 Q4 transcript, 12-Feb-2026]. The exit rate (4.2%) is materially better than the full-year average (3.5%) — the bull’s strongest trajectory data point. INTERPRETATION: the Q4 step-up is real but flattered in places by weak prior-year comparators (Indonesia +17% Q4 against a soft base) and easy EM comps — recovery from self-inflicted 2024 damage, not pure underlying acceleration.

Organic vs. acquired, and the Power-Brand premium. Growth is organic; M&A is a small net negative to turnover. In FY25, acquisitions (Minimalist, Wild, Dr. Squatch) added just +0.6% to turnover, more than offset by −1.8% of disposals (net A&D −1.2%). FX was a −5.9% headwind, so reported turnover fell 3.8% even though USG was +3.5%. UL’s growth algorithm is fundamentally organic — bolt-ons are portfolio-shaping, not a growth crutch (a quality positive, with no roll-up flattering) — but it also means the disappointing organic number is the real number, with nowhere to hide. The 30 Power Brands = ~78% of turnover and grew 4.3% USG (volume +2.2%), ~80bps faster than the group, accelerating to 5.8% in Q4; 100% of incremental brand-and-marketing investment went to Power Brands. Conversely, the non-Power-Brand 22% of revenue had volume of −1% for the year, worsening to −3% in Q4. This is a deliberate two-speed portfolio — feed the winners, prune the tail — the right strategy, but it mechanically means reported group growth is dragged by a shrinking-but-still-large 22% tail; the honest read sits between the Power-Brand and group numbers.

Segment growth — Beauty/PC lead, Foods/Home Care lag. Within Beauty & Wellbeing (the strategic engine, 4.3% USG), Wellbeing (Liquid I.V. crossed $1bn and >18% US household penetration; Nutrafol +23%; OLLY +9%, now >$500m) delivered double-digit growth and is the highest-quality sub-segment; Prestige Beauty only grew low-single-digit (Hourglass/K18 double-digit, but Dermalogica and Paula’s Choice only “returned to growth in H2”), and core Hair Care was flat. Personal Care had the best USG (4.7%) but price-led (3.6% price vs 1.1% volume). Home Care was healthily volume-led (2.2% vol / 0.4% price) but lowest growth (2.6%) and lowest margin (14.9%). Foods was the laggard (2.5%, volume only 0.8%) at a record 22.6% margin (+130bps) — but management explicitly pivoted Foods to “drive growth, volume-led, not big margin expansion,” an admission the margin was harvested by pruning, not earned by volume. Geographically, North America was the standout (+5.3% USG, volume +3.8%, a ~4% NA volume CAGR over three years) — the genuine bright spot and the proof the operating model works where fully deployed; Latin America +0.5% (price +5.9% / volume −5.1%) is a textbook over-pricing-into-elastic-demand error; China was flat; Indonesia’s +17% Q4 is recovery off self-inflicted 2024 own goals.

Forward drivers. Four legs: (1) premium beauty & “Wellbeing” health — K18, Hourglass, Paula’s Choice (relaunch Mar-2026), Dermalogica, Nutrafol, Liquid I.V., OLLY, plus Dr. Squatch (enters USG Sept-2026) and Wild/Minimalist — the highest-multiple, US/e-commerce-skewed part and the explicit M&A target zone (caveat: Wellbeing decelerated in Q4 on a Liquid I.V. club-channel assortment loss and rising Nutrafol acquisition cost — the DTC growth is not frictionless); (2) EM penetration (India record share, China reset); (3) “fewer, bigger, better” innovation (Persil Wonder Wash in 30+ markets, Dove fiber-repair, Vaseline Gluta-Hya), with BMI raised to 16.1% of turnover (a decade high, +300bps over four years); (4) the GAP2030 algorithm — mid-single-digit USG (4–6%) and modest margin expansion. FY26 guidance: USG at the bottom of 4–6% (~4%), volume ≥2%, modest margin improvement — guiding to the bottom of the range, in the first full year of the “new, simpler Unilever,” is a tacit admission that 4–6% is aspirational and ~4% realistic.

Verdict: low-to-medium-quality growth — improving at the margin, structurally sub-peer, and not yet proven. For three of the last five years “growth” was inflation pass-through with volume loss — the lowest-quality form there is. The 2024–25 volume recovery is real and is the bull’s foundation, but FY25 USG of 3.5% undershot the company’s own floor, volume decelerated year-on-year, the Q4 exit rate leans on weak comps, and FY26 is guided to ~4%. The quality mix is genuinely improving (Power Brands ~78% growing 4.3–5.8%, BMI at a decade high, a good US franchise, a high-growth premium-beauty/Wellbeing tail). But the laggards are structural and the whole forward case requires the new model to convert into consistent mid-single-digit volume-led growth it has not demonstrated for a full cycle. Better-quality, not yet high-quality; the burden of proof is squarely on management.

6. Financial Quality

Revenue composition and trend. FY25 turnover was €50,503m, down ~3.8% reported — an optical artifact of the in-year Ice-Cream deconsolidation and FX, not a demand problem; the steered metric, USG, was +3.5%. Over five years turnover ran €50.7bn (FY19) → €60.1bn (FY22 peak, inflation-led pricing) → €51.7bn (FY23) → €52.5bn (FY24) → €50.5bn (FY25), the step-down driven by the Ice-Cream carve-out and tail-brand pruning rather than core erosion. The crux for the bull is the volume recovery — FY25’s ~+1.5% volume is the cleanest signal, because volume-led growth on a staples portfolio is far higher quality than the 2022–23 price-led spike. UL’s organic profile sits between P&G (low-single-digit, premium-mix-led) and the slower Colgate/Kimberly-Clark cohort; it is not a structurally faster grower than P&G despite comparable scale.

Margin trajectory — the post-inflation recovery. Gross margin recovered from a trough of 40.2% (FY22) to 43.5% (FY23) to 46.7% (FY24) to 46.9% (FY25) — a ~670bps rebuild as input costs deflated and pricing held. Underlying operating margin reached 20.0% in FY25 (up from the 16.2% FY22 trough), back above the pre-inflation ~18.5–19.1% band. The margin story is genuinely good and the single best evidence of pricing power. The counter-argument: the 20.0% is partly a portfolio-mix gift (exiting lower-margin Ice Cream/Foods lifts the average), and incremental operating margin of ~7.6% (FY25) is unremarkable — the business is not showing strong operating leverage on incremental revenue. Margin gains came from gross-margin recovery and overhead discipline, not a widening flywheel.

Quality of Earnings (QoE) — the load-bearing subsection. Read this before using any P/E on this name.

• (a) GAAP total EPS is inflated by a one-off demerger gain — do NOT use it. FY25 statutory total diluted EPS was €4.34, contaminated by an ~€3.8bn discontinued-operations gain on the Ice-Cream demerger. Continuing-operations EPS was materially lower, and the metric to anchor to is underlying EPS of €3.08 (+0.7% reported, FY25). The AZI/aggregator headline P/E of ~11x — dividing price by €4.34 — materially overstates cheapness. On underlying EPS €3.08 (≈$3.3), the multiple is ~17–18x — an in-line-to-slightly-rich staples multiple, not a bargain. This is the single most important QoE correction in the report.
• (b) Heavy reliance on “underlying” non-GAAP metrics. UL steers the whole story (USG, underlying operating profit/margin/EPS, underlying ROIC) on a non-GAAP basis. The adjustments are mostly legitimate and the FY25 underlying/statutory operating-profit gap is modest — but the framework is management-defined and must be reconciled, not taken on faith.
• © Restructuring runs persistently through “non-underlying.” UL has charged restructuring as “non-underlying” essentially every year (the multi-year GAP, productivity programmes, ~7,500 role cuts). A “one-off” that recurs annually is a de facto operating cost; clean owner-earnings sit ~50–100bps below reported underlying operating profit.
• (d) FX is a large, recurring swing factor. FY25 underlying EPS grew +0.7% reported but +9.5% constant-currency — an ~8.8% FX drag. With ~60% of profit from EM, reported euro results are chronically buffeted by EM-currency weakness; any clean read of momentum must use constant-currency.
• (e) Cash conversion is high and clean. Operating cash flow was €8,350m, FCF €5.9–6.8bn; multi-year FCF has been a steady €5.6–8.0bn. Working-capital swings are noisy quarter to quarter but net to the structural FMCG benefit. No accrual-quality red flag in the cash statement.

Free cash flow, capex, working capital. Capex was €1,591m, ~3.2% of sales — genuinely asset-light; FCF of €5.9–6.8bn comfortably funds dividend + buyback. Working capital is structurally negative (suppliers finance the trade; a negative cash-conversion cycle) — a recurring FMCG funding benefit that flatters returns and reduces tied-up capital. This cash-generative, low-capex, negative-working-capital profile is the most attractive financial feature of the business.

ROIC and its DOWNWARD drift — the Marathon flag.

*ROE is distorted by the small/negative-tangible-equity base and one-off gains — do not lean on it. INTERPRETATION (Marathon lens): the central financial-quality concern. Even as margins fully recovered (gross +670bps), computed ROIC did NOT recover — it stalled at ~14% vs 17.4% in FY19, a ~300bps structural step-down. The reason is the denominator: a decade-plus of goodwill- and intangible-heavy M&A (Dollar Shave Club, the premium-beauty roll-up, Horlicks/GSK India) bloated invested capital faster than incremental returns. In Marathon terms, capital was added at returns below the legacy base — the classic signature of a serial acquirer diluting marginal returns even while headline profit grows. ROIC at ~14% still clears WACC (~7–8%), so this is a good business — but a decreasingly good one, and the burden of proof is on management to show the reshaping reverses the drift rather than merely shrinking the base.

Balance sheet — leverage, negative tangible equity, liquidity. Closing net debt €23.1bn (down from €24.5bn at FY24-end), net-debt/underlying-EBITDA ~2.0x — investment-grade and within the staples norm (P&G ~0.5–1x is lower; UL runs more levered but not stressed). Total debt €27.6bn against €3.9bn cash. Total equity €17.6bn (incl. €2.06bn minority). Critically, tangible equity is deeply negative: goodwill €17.7bn + other intangibles €17.1bn (~€34.8bn) exceeds total equity, so net of acquired intangibles book equity is negative ~€17bn — the accounting residue of decades of premium-priced M&A. This is not distress, but it (i) makes ROE meaningless as a quality gauge (use ROIC) and (ii) underscores that a large slice of EV is purchased goodwill whose returns are the very thing drifting down. Liquidity is ample; the mature defined-benefit pension is broadly funded and not a material overhang. The €15.7bn cash inflow from the McCormick deal will be available to de-lever and/or return.

Verdict (Financial Quality): HIGH cash-flow quality, MODERATE-and-slipping return quality, and a headline EPS materially overstated by a one-off. Unilever is a genuinely cash-generative, asset-light, pricing-powered franchise whose margins fully recovered above pre-COVID levels and whose FCF is clean and well-covered. But economics are NOT improving with scale — ROIC fell from 17.4% (FY19) to ~14.3% (FY25) despite a full margin recovery, because goodwill-heavy M&A diluted returns (Marathon red flag). On earnings quality, the GAAP EPS of €4.34 is inflated ~€1.26 by the demerger gain and must be discarded; the correct base is underlying EPS ~€3.08, on which the stock is not cheap (~17–18x, not the ~11x screen). Net: a good-but-not-great business at a fair-to-slightly-rich price once the QoE corrections are applied.

7. Capital Allocation

The framework: a portfolio-reshaping (subtraction) story. Unilever’s capital allocation over five years is best understood as a subtraction strategy — shrinking and re-mixing toward higher-growth, higher-margin Beauty/Wellbeing and Personal Care while exiting slow, low-multiple categories. The Greenwald/Marathon question is whether this is intelligent shrink-to-grow or financial engineering that destroys the scale underpinning the moat. The evidence is mixed-to-cautiously-favourable on recent moves, clearly negative on prior-era big bets.

Dividend. Unilever paid €4,453m in FY25 (payout ~66% of underlying earnings; ~3% yield) — a long, uninterrupted record. At the Ice-Cream demerger it executed an 8-for-9 share consolidation so per-share dividend/price are mechanically comparable post-spin. Conservative, sustainable capital return; no concerns.

Buybacks and share count. Buybacks have run a steady ~€1.5bn/yr (FY25 €1,510m), with a fresh €1.5bn programme for 2026. Share count fell from 2.62bn (2017) to ~2.18bn (FY25) — ~17% over eight years, modestly accretive. SBC is tiny (€255m, ~0.5% of sales), so buybacks are genuine net shrinkage, not dilution-offset — a clean positive. But buybacks are not aggressive relative to FCF: Unilever returns ~all of FCF via dividend + buyback combined, leaving little for de-leveraging absent disposals.

M&A track record — the good, the bad, the disciplined restraint. The value-destructive prior era: Dollar Shave Club (~$1bn, 2016) — a flagship “DTC disruption” bet that never scaled, sold to Nexus Capital in 2023 at a clearly nominal value, a near-total write-down; the failed £50bn GSK Consumer Health bid (Jan-2022) — rejected and abandoned after a shareholder revolt, which triggered the Peltz/Trian stake (had it completed it would have been a transformational, debt-funded, arguably value-destructive megadeal — its failure was value-preserving); Horlicks/GSK India (2020, ~€3.3bn) — a premium price for a malted-drink asset of debatable fit. The more disciplined recent bolt-ons (Liquid I.V., Nutrafol, Paula’s Choice, K18, Minimalist, Wild, OLLY, Dr. Squatch 2025 ~$1.5bn) roll up high-growth, higher-margin prestige/wellness brands; FY25 acquisition spend was €1,674m, within FCF. INTERPRETATION: the recent bolt-on strategy is directionally sensible — buying demand-side captivity in faster-growing niches — but it is precisely this acquired-intangible accumulation that is diluting ROIC. Several (DSC, parts of the early prestige-beauty book) disappointed. The single most favourable data point is what management REFUSED to buy — walking away from the £50bn GSK deal avoided a catastrophic capital sink; restraint created more value than activity.

Portfolio reshaping AS capital allocation — the two big exits. This is the heart of the current thesis. Ice Cream demerger (completed Dec-2025): the ~€8bn-revenue Ice Cream business spun off as The Magnum Ice Cream Company, listed Amsterdam/London/New York, producing the ~€3.8bn discontinued-ops gain; rationale was its structurally different (capital-intensive, cold-chain, seasonal, lower-margin) model. Foods → McCormick (announced 31-Mar-2026) — detailed in — a $44.8bn Reverse Morris Trust that is tax-efficient, monetises Foods at a credible value (~3.3x revenue), hands shareholders a stake in a focused leader rather than dis-synergistic cash, and leaves a cleaner RemainCo. INTERPRETATION: broadly intelligent shrink-to-grow, with two caveats — (1) Unilever is handing away scale (Foods + Ice Cream were ~€18bn of the old ~€60bn base; if the moat partly rests on scale-driven distribution/procurement, fragmenting could erode the cost advantage the RemainCo mix must more than compensate for); (2) receiving MKC stock, not cash, makes the outcome hostage to McCormick’s execution and multiple.

R&D and brand/marketing intensity. R&D runs ~€1bn (~2% of sales) — appropriate for FMCG (advantage is brand/distribution, not patents). Brand & marketing investment (BMI) runs ~€8–9bn, ~15%+ of sales — the real “R&D” and the maintenance capex of the moat. The ~15% BMI intensity is the structural cost of demand-side captivity and is consistent with peers; under-spending it would harvest the brand. R&D at ~2% confirms the moat is brand, not technology.

Verdict (Capital Allocation): IMPROVING and currently rational, but burdened by a poor prior record and unproven that the reshaping reverses the return drift. The base policy (sustainable ~66% payout, ~3% yield, steady ~€1.5bn buyback, tiny SBC) is conservative and shareholder-friendly; the recent moves (Ice-Cream demerger, the tax-efficient McCormick RMT, the discipline of walking away from GSK) are sound and focus-creating. But the historical M&A record is poor, and the premium-beauty roll-up is the proximate cause of the ROIC drift. The verdict hinges on a forward bet: if the focused RemainCo + McCormick stake + de-levered balance sheet lift returns toward the high-teens, this is good allocation; if management has merely engineered a smaller, equally-mid-return business, it is value-neutral reshaping. Cautiously positive on the present trajectory; the burden of proof is on management to show returns — not just the revenue base — improve.

8. Changes and Headwinds — Last Two Years

(a) Ice-Cream (Magnum Ice Cream Company) demerger — the defining event. Unilever demerged its entire ice-cream business as The Magnum Ice Cream Company N.V. (Magnum, Ben & Jerry’s, Wall’s, Cornetto), admitted to trading on Euronext Amsterdam (primary), LSE and NYSE on 8 December 2025; an 8-for-9 share consolidation followed. Ice cream was a ~€8bn-revenue, lower-margin, highly seasonal, capital-intensive business. Post-demerger, FY25 gross margin is structurally higher (46.9%) and the income statement carries a ~€3.8bn discontinued-ops gain that inflates FY25 GAAP EPS to €4.34 vs underlying €3.08. INTERPRETATION: thesis-strengthening on quality — it removes the lowest-margin, most capital-hungry, least-on-strategy unit, lifting structural gross margin and ROIC. Caveats: (i) the ~€3.8bn gain makes FY25 GAAP EPS useless as run-rate; (ii) it removes ~€8bn of revenue, so reported-turnover decline is partly mechanical; (iii) a tapering Transition Services Agreement remains.

(b) Foods → McCormick combination (announced 31-Mar-2026) — the new, larger move. Unilever is combining its global Foods division (~€13.4bn revenue; Knorr ~€5bn, Hellmann’s ~€3bn) with McCormick & Co (NYSE: MKC) in a $44.8bn Reverse Morris Trust [FACT — SEC Form 425 (CIK 217410); Unilever & McCormick press releases, 31-Mar-2026; Food Dive / FoodNavigator]. Mechanics: Unilever’s Foods is distributed to Unilever shareholders and immediately merged into McCormick; McCormick borrows to pay Unilever $15.7bn cash and issues ~$29.1bn of new stock; post-deal, Unilever shareholders own ~55.1% of each class of McCormick, Unilever retains ~9.9%, legacy McCormick holders ~35%. So UL shareholders receive MKC shares directly while the cash goes to Unilever the company. The structure is generally tax-free for US federal tax (RMT). Scope: the combined McCormick has ~$20bn revenue with ~$600m run-rate cost synergies; Lipton RTD, Buavita, lifestyle nutrition and Foods ops in India/Portugal/Nepal are retained by Unilever. Expected close mid-2027. Result: post-both-exits, Unilever becomes a focused Beauty/Wellbeing, Personal Care, Home Care company of ~$40–44bn revenue, plus $15.7bn cash + a ~9.9% MKC stake. INTERPRETATION: the most consequential capital-allocation decision in years — tax-smart, focus-creating, monetising a slow-growth division at a credible value — but it trades scale for focus and hands shareholders acquirer stock rather than clean cash (a bet on McCormick’s execution, see ).

© CEO change — Schumacher out after <2 years, Fernandez in. Hein Schumacher stepped down as CEO effective 1 March 2025 (after ~18 months), replaced by then-CFO Fernando Fernandez (a long-time EM operator: President Latin America, CEO Brazil/Philippines, President Beauty & Wellbeing); Srinivas Phatak became CFO. INTERPRETATION: a CEO ousted after ~18 months is a governance red flag — Schumacher authored the GAP and the ice-cream split yet was removed before delivering them. The market read it as the board (with Peltz) wanting a faster operator. Net: continuity of strategy with a sharper operator — modestly positive operationally, but the abruptness underscores a company still searching for stable leadership (Polman→Jope→Schumacher→Fernandez).

(d) Growth Action Plan / GAP2030. Launched by Schumacher Oct-2023 (concentrate on 30 Power Brands, drive volume-led USG, expand gross margin, improve productivity), refreshed as GAP2030 at the Nov-2024 Capital Markets Day. Sound and orthodox; working where deployed (Power Brands +4.3%, BMI 16.1%, gross margin +330bps/3yr, US ~4% volume CAGR) — but FY25 USG 3.5% is below the ambition and FY26 is guided to the bottom of the range. Directionally validated, quantitatively unproven against its own headline target.

(e) Productivity Programme — ~€800m / ~7,500 roles. Announced Mar-2024; by FY25, >€670m cumulative savings delivered, “well ahead of plan,” on track to complete €800m in 2026. Overheads fell ~50bps in FY25. A clear positive — ahead of schedule and flowing to the +60bps underlying-margin expansion.

(f) M&A rotation. Acquisitions (Dr. Squatch ~$1.5bn at ~3.7x revenue — a full price; Minimalist, Wild, K18, Nutrafol, Liquid I.V., OLLY — “10 deals in 2025, ~15% of portfolio rotated”) vs disposals (Graze → Katjes; Elida Beauty/Suave; Conimex, Unox, The Vegetarian Butcher). Strategically coherent (rotate out of low-growth local lines into premium/digital/US-skewed categories) but the prices are full and the bolt-ons are small relative to the €50bn base, while disposals subtract visible revenue now.

(g) Activist Nelson Peltz / Trian. Peltz has been a Non-Executive Director since 20 July 2022 (Remuneration Committee), re-elected Apr-2025 with 98.03% support, though Trian has been trimming its stake. The activist throughline runs behind the whole transformation arc (GAP, demerger, productivity cuts, portfolio rotation) — net positive on discipline, but a reminder that the easy activist wins are largely done, limiting the remaining catalyst set; Trian’s trimming is a “mission accomplished” tell worth monitoring.

(h) Guidance / margin path / headwinds. FY25 delivered USG 3.5%, underlying operating margin 20.0% (+60bps), gross margin 46.9%, underlying EPS €3.08 (+0.7% reported / +9.5% constant-currency — currency a −8.8% headwind). FY26 guide: USG bottom of 4–6%, volume ≥2%, modest margin improvement. The margin/EPS path is the most credible part of the story; the weak spot is that hard-currency EPS growth is structurally fragile (FX ate ~8.8% in FY25) and EPS growth leans partly on the buyback and a lower tax rate.

Verdict: the changes STRENGTHEN the thesis on quality and discipline, but they are largely backward-looking self-help — the heavy lifting is done and the remaining catalyst set is thin. Unilever is unquestionably a higher-quality, simpler, more-focused business than in 2023: the demerger lifts structural margin/ROIC, productivity is ahead of plan, M&A rotates toward premium/Wellbeing/US-digital, and an activist plus a sharper EM-operator CEO have instilled discipline. But — as management itself voiced — “the heavy lifting has been done”: the big unlocks are executed or in train, the Foods-separation optionality is now spent via McCormick, and what remains is the hard part — converting self-help into consistent, mid-single-digit, volume-led organic growth that has not yet appeared (FY25 USG 3.5%, FY26 ~4%, reported EPS +0.7%). The changes de-risked the quality; they have not yet proven the growth.

9. Risk Analysis (Risk Matrix)

Net: the dominant risks are growth durability (#1), the return drift (#3) and capital redeployment of the McCormick cash (#4/#5) — all execution/capital-allocation risks, not solvency risks. There is no catastrophic-loss risk in a diversified, defensive, investment-grade staples franchise; the realistic downside is dead money / mild de-rating, not impairment.

10. Valuation Discussion — Embedded Expectations

Where UL trades today (ADR ~$60.55; aggregated data FY25/TTM, reconciled):

The two “do-not-be-fooled” nuances. (1) The headline GAAP P/E (~11–13x) is a mirage — inflated DOWN by the one-time demerger gain. On underlying EPS €3.08, the multiple is ~17–18x, a ~20–25% discount to P&G (~20x fwd) and a much larger discount to Colgate — a meaningful but ordinary quality-gap discount, NOT the dramatic ~50% the headline 11x implies. (2) EV/EBITDA at 14.4x is modestly cheap vs UL’s OWN history (10-yr band 14.4–16.6x; 14.4x is the bottom) and roughly in line with peers (PG 15.9x, CL 15.9x, Nestlé ~14.1x) — UL is not cheap on an absolute staples basis, but at the low end of its own range and a touch below its closest mega-cap peers.

Peer comp (June 2026; ROIC TTM unless noted):

On the clean, comparable measures (EV/EBITDA and underlying/forward P/E), UL sits at or slightly below the mega-cap pack — ~14.4x EV/EBITDA vs PG/CL ~15.9x and Nestlé ~14.1x; ~17–18x underlying P/E vs PG ~20x fwd, Nestlé/Reckitt/Beiersdorf ~17–18x fwd, Colgate ~24x fwd. UL is priced as a mid-pack-to-slightly-cheap staples name, not a deep-value wreck.

SOTP / transformation angle. UL is mid-way through a two-step amputation converting a sprawling food-plus-HPC conglomerate into a focused Beauty & Wellbeing / Personal Care / Home Care pure-play: Step 1 (done, Dec-2025) Ice Cream demerged; Step 2 (announced 31-Mar-2026, closes mid-2027) Foods → McCormick $44.8bn RMT, leaving UL holders with (a) shares in the focused RemainCo, (b) McCormick stock (directly + via UL’s 9.9% stake), and © $15.7bn cash into UL’s balance sheet to redeploy. The SOTP argument: the legacy conglomerate carried a “sum-of-mediocre-parts” discount; a BPC-and-Home-Care pure-play growing mid-single-digit USG at ~20%+ underlying op margin arguably deserves a multiple closer to L’Oréal/Beiersdorf/premium-beauty peers than to a food conglomerate — a re-rating option the price gives no credit for. The bear retort: the parts being sold (Foods, Ice Cream) were stable cash generators; selling them raises portfolio quality but shrinks the earnings base, and the re-rate only materializes if RemainCo out-grows and the McCormick stake/cash is redeployed accretively.

Embedded expectations / reverse-DCF. Holding UL’s ~$146bn EV against RemainCo economics (~€40bn revenue, ~20%+ underlying op margin, ~mid-single-digit USG post-Foods), at 14.4x EV/EBITDA on a high-quality ~3–4% organic grower throwing off a ~12% FCF yield, the market is underwriting roughly: mid-single-digit USG (~3–4%), underlying operating margin holding ~20% and edging toward the GAP2030 ambition, and ~mid-single-digit underlying-EPS growth — i.e. the company roughly delivering its own algorithm, with NO premium for a successful BPC re-rating. To justify a re-rate toward PG (~16x EV/EBITDA / ~20x earnings, ~10–15% higher), RemainCo must demonstrate sustained 4%+ USG with positive volume and margin accretion through the Foods close. Pricing CORRECTLY: UL is a genuine mid-single-digit grower again (the discount to PG has already narrowed from 2022 depths); EM-FX is a real recurring drag warranting some discount; two-step break-up + redeployment is non-trivial execution risk. Pricing INCORRECTLY (potentially): zero credit for the SOTP re-rating if RemainCo lands clean; possible over-discount of a team that has now strung together ~2 years of delivery (the “perennial disappointer” tag may be stale); the headline 11x optics depress sentiment even though sophisticated holders see ~17–18x.

Scenarios (explicit assumptions; NO price target):

No price target and no buy/sell, per .

11. Variant Perception

Consensus view. UL is a sub-peer grower and perennial disappointer — a decade of “this time we re-accelerate” promises that mostly didn’t, structurally exposed to EM/FX translation drag, that deserves its discount to PG/Colgate. The market grants it a mid-pack staples multiple (~14x EV/EBITDA, ~17–18x underlying earnings) — neither a wreck nor a compounder, a “show-me” stock.

Factor-positioning read (FACT — FactorsToday). An abandoned, low-volatility defensive / quality-at-a-discount name with a recent positive inflection — NOT momentum and NOT a falling knife. Beta just 0.12; strongly defensive (BetaFactor −0.46, LowVolatility +0.24), modest Quality +0.14, a UK-country tilt +0.28, and a USDollar −0.29 loading (benefits when USD weakens — a EUR/GBP reporter). Crucially NO Momentum and NO Value loading — the market has neither chased it nor classed it as a deep-value play; it is simply un-owned by the factor crowd. Relative strength is persistently negative (RS_6m −6.6, RS_12m −9.3, RS_peak −17.4), and the leaderboard confirms dead money (5-yr +1.2%/yr, Sharpe −0.04; y1 −8.4%, m6 −12.9%). But m3 is +12.4% annualized — a recent bounce/inflection, not a knife. Factor-similar peers: CCEP, PG, CL. This supports a contrarian quality-at-a-discount framing, with the tape only just turning.

Strongest bull case. Two-step portfolio surgery manufactures a higher-quality, higher-margin, faster-growing BPC pure-play that re-rates toward P&G. Ice Cream is gone; Foods goes to McCormick for $44.8bn — leaving a focused ~€40bn Beauty/Personal/Home Care business at ~20%+ underlying margin. Volume growth has returned, GAP2030 + €800m productivity are landing, the stock is at the low end of its own 10-yr EV/EBITDA band, and activist Peltz/Trian is on the board and aligned with exactly this playbook. The SOTP re-rate option is free in today’s price.

Strongest bear case. A decade of broken re-acceleration promises, now selling its ballast. Foods and Ice Cream were stable cash — divesting them raises quality optics but shrinks the base, and the entire thesis hinges on (a) RemainCo actually out-growing, (b) the McCormick stake + cash being redeployed well (UL’s M&A history — GSK, the premium-beauty roll-up — is the textbook risk), and © overcoming a structural EM-FX drag that recurs every year. Strip the optics and RemainCo is still a sub-P&G grower; the discount may be deserved, and the recent inflection may be cyclical, not structural.

The assumptions that matter most + falsification tests:

Synthesis: the factor read (un-owned, defensive, low-vol, no momentum/value loading, just-inflecting) is consistent with a contrarian quality-at-a-discount setup where consensus is offsides on the durability of the turnaround and gives no credit for the transformation option — but the bear’s point that the recent move may be cyclical, and that selling the cash legs raises the bar, is the live risk. The tie-breaker is assumption #1 (sustained positive-volume USG).

12. Fact vs. Interpretation Table

13. Open Questions

1. RemainCo pro-forma economics — the exact post-Foods revenue, margin, USG and ROIC of the standalone Beauty/Wellbeing/Personal Care/Home Care company (sizing is currently inferred from FY25 segment data).
2. McCormick stake & cash redeployment — will the ~9.9% MKC stake be held, monetized, or distributed? Will the $15.7bn cash fund buybacks, de-leveraging, or further premium-beauty M&A (the GSK-redux risk)?
3. Insider conviction — UK filing means no Form 4 corpus; confirm via FY25/26 RNS director-dealing notices whether any discretionary on-market purchases occurred around the demerger/McCormick announcements (none evident so far).
4. Premium-beauty durability — is the Q4 Wellbeing deceleration (Liquid I.V. channel loss, Nutrafol CAC) a blip or the start of mean-reversion in the buzzy DTC tail?
5. Trian’s exit timing — at what point does the activist declare victory and leave, and does discipline fade with it?
6. McCormick close risk — regulatory clearance and market conditions for a mid-2027 close; what happens to the thesis if the RMT slips or breaks?
7. Company “underlying ROIC” (~19%) vs computed ROIC (~14%) — reconcile the two definitions precisely (invested-capital base, goodwill treatment) to judge which the pay plan actually rewards.

14. What Must Be True (Bull and Bear, with Falsification Tests)

Bull case — what must be true: RemainCo is a structurally faster, higher-quality grower than the legacy conglomerate — sustaining 4%+ underlying sales growth with positive volume through the Foods close, holding/expanding the ~20% underlying operating margin toward the GAP2030 ambition, redeploying the McCormick cash + stake accretively (buybacks / disciplined bolt-ons, not a megadeal), and earning a multiple re-rating toward premium-BPC peers as the focused pure-play emerges. Falsification test: if, over the next 3–4 quarters, USG slips back to 2–3% with flat/negative volume, or management announces a large, richly-priced premium-beauty acquisition that re-bloats invested capital, the bull thesis is broken — UL is confirmed a serially sub-peer grower whose surgery merely shrank the base.

Bear case — what must be true: the discount is deserved — RemainCo remains a sub-P&G grower dragged by EM-FX, the recent volume recovery is cyclical not structural, selling the stable Foods/Ice-Cream cash legs raises optics but not durable returns, and the McCormick stock/cash is squandered or held idle. Falsification test: if RemainCo sustains 4%+ USG with positive volume through the Foods close, the underlying operating margin grinds to ~21–22%, the McCormick stake is monetized at/above fair value with the cash funding buybacks, and the multiple expands toward ~16x EV/EBITDA / ~20x earnings, the bear thesis is broken — the transformation will have manufactured a genuine re-rating the market under-priced.

15. Source Appendix

Selected primary sources (full list in Appendix B): Unilever FY2025 Full Year Results (12-Feb-2026) and Annual Report & Accounts 2025; Unilever Q1–Q4 2025 earnings-call transcripts (aggregated data); SEC Form 425 / 6-K corpus (CIK 217410) and Unilever/McCormick press releases on the Foods combination (31-Mar-2026); aggregated data fundamentals (income statement, balance sheet, cash flow, profitability ratios, enterprise value, valuation multiples, per-share data); valuation-index and news feed; FactorsToday factor model (loadings, leaderboard, specific vol, related stocks); 5-year price history. All data accessed 2026-06-27.

APPENDIX A — Standard Diligence Questionnaire — Unilever PLC (NYSE: UL)

Report date 2026-06-27. Grounded in the research notes. Labels: F = Fact, I = Interpretation, A = Assumption. Figures EUR unless noted; ADR ~$60.55.

General

What thoughtful questions have other investors asked about this company? (I) The dominant investor questions are: (1) Is the volume recovery (2024–25) structural or just a cyclical bounce off self-inflicted 2024 EM own-goals? (2) Does the two-step portfolio surgery (Ice Cream demerged, Foods → McCormick) actually create a re-rating, or just shrink a mid-return business? (3) What happens to the $15.7bn McCormick cash and the ~9.9% MKC stake — buybacks, de-leveraging, or another expensive premium-beauty deal? (4) Why has computed ROIC drifted down (17→14%) despite a full margin recovery? (5) Is the ~11x headline P/E “cheap,” or an artifact of the demerger gain (it is the latter)?

Cyclicality & Earnings Nature

Cyclical high or low? (I) Margins are at a cyclical-to-structural recovery high (gross 46.9% vs 40% FY22 trough; underlying op margin 20.0%) — the post-inflation rebuild is essentially complete, so further margin gains must come from mix/productivity, not recovery. Growth is mid-cycle (volume returned but USG 3.5% is sub-trend). Internal or external drivers? (I) Both — the margin recovery is part input-cost deflation (external) and part GAP/productivity (internal); the volume recovery is part EM-comp normalization (external) and part GAP execution (internal). Revenue stability? (F) Very stable — daily-use, repeat-purchase staples; defensive (beta 0.12); the variability is in reported (FX) not underlying demand. Outlook for products? (I) Mature, low-single-digit-growth categories with EM penetration runway; premium beauty/wellbeing the fastest sub-segment. Market size — growing/shrinking, domestic/international? (F) Global (~190 countries, ~59% emerging markets), low-single-digit value growth; a mature, international, slow-growing market.

Business Quality & Competitive Moat

Industry more or less competitive? (I) Stable-to-slightly-more competitive — rational among the scaled majors, but private label and DTC challengers pressure the edges. How profitable (ROIC/ROE)? (F) Computed ROIC ~14% (company “underlying ROIC” ~19% on its own definition); ROE 20.1% is a negative-tangible-equity artifact — use ROIC. How profitable is the industry / barriers? (F/I) Attractive for scaled leaders (high gross margins, high barriers from brand/scale/distribution); brutal for the unscaled. Easily understood? (F) Yes — a branded-FMCG royalty. Undermined by low-cost foreign labor? (I) No — the moat is brand preference + distribution, not low-cost manufacturing; private label is the relevant low-cost threat. Do brands matter? (F) Yes — they are the entire moat (~78% of turnover from 30 Power Brands; ~15%+ of sales spent defending them). Nature of competition? (I) Innovation, advertising, distribution and premiumization — not destructive price (except commodity Home Care). Switching costs? (F) Near-zero for consumers — captivity is habit, not lock-in.

Financial Condition & Balance Sheet

Assets not on the balance sheet? (I) Yes — enormous brand equity (Dove, Knorr, Hellmann’s) is largely internally generated and unrecognized; conversely, ~€34.8bn of acquired goodwill/intangibles is on the sheet. Off-balance-sheet liabilities? (I) None material flagged; mature DB pension broadly funded; standard operating leases capitalized. How conservative is the accounting? (I) Moderate — clean cash conversion (no accrual red flag), but heavy reliance on management-defined “underlying” metrics and persistent “non-underlying” restructuring (a de facto recurring cost) require active reconciliation. CapEx-hungry? (F) No — capex ~3.2% of sales, asset-light, negative working-capital cycle.

Capital Allocation & Management

FCF generation and use? (F) FCF ~€5.9–6.8bn; used for dividend (~€4.5bn, ~66% payout) + buyback (~€1.5bn) — essentially all of FCF returned. Philosophy? (I) Shrink-to-grow portfolio reshaping + steady shareholder return; improving discipline (ROIC in pay, walked from GSK) but a poor prior record. Significant acquisitions? (F) Yes — Dr. Squatch (~$1.5bn, 2025), plus a string of premium-beauty/wellbeing bolt-ons; the big move is the divestiture (Foods → McCormick $44.8bn RMT). Buying back shares? (F) Yes, steady ~€1.5bn/yr; share count 2.62bn (2017) → 2.18bn (2025). Issuing shares to insiders? (F) Minimal — SBC ~€255m (~0.5% of sales). Compensation policy? (F) PSP = underlying ROIC 30% + relative TSR 30% + USG 25% + sustainability 15%; annual bonus on USG/op-profit/FCF — well-designed, ROIC-aligned (better than US peers with no ROIC metric). Motivations of management? (I) Internal EM-operator CEO (Fernandez) focused on volume/margin/portfolio; aligned activist (Peltz) on board; but serial CEO churn signals a still-unsettled strategy.

Valuation & Market Data

ADR, MLP, or K-1? (F) ADR (1 ADR = 1 ordinary share; UK PLC). Not an MLP; no K-1 — issues a standard 1099/dividend; US holders may face UK/Dutch withholding considerations on dividends (consult the custodian). Dividend policy? (F) Quarterly EUR dividend, ~66% payout, ~3% yield, long uninterrupted record; ~70/30 dividend/buyback split. How profitable? (F) Mid-teens ROIC, 20% operating margin, 47% gross margin — good, not great. Net income vs cash from operations diverging? (F) No structural divergence — FY25 CFO €8,350m vs net income €6,213m (continuing); cash conversion is clean (the divergence is the demerger gain in GAAP net income, not a cash-quality issue).

Risks & Downside

What causes the stock to decline? (I) Volume rolls over / USG slips to 2–3%; a dilutive megadeal redeploying the McCormick cash; EM-FX shock; the McCormick close slips/breaks; the multiple stays stuck while peers re-rate; staples sector de-rating. Catastrophic loss risk? (I) Very low — diversified, defensive, investment-grade (2.0x net debt/EBITDA), no single point of failure. Total loss? (I) Negligible — the realistic downside is dead money / mild de-rating, not impairment.

Recent News & Events

Business environment changed recently? (F) Yes, materially — (1) Ice-Cream demerger completed 8-Dec-2025 (The Magnum Ice Cream Company); (2) Foods → McCormick $44.8bn RMT announced 31-Mar-2026 (closes mid-2027); (3) CEO change Schumacher → Fernandez (Mar-2025); (4) ~€800m productivity programme ahead of plan; (5) premium-beauty bolt-ons (Dr. Squatch) + local-foods disposals (Graze); (6) June-2026 press: UL exploring a bid for supplement maker Thorne (~$4bn), and an Accenture AI manufacturing partnership. Accounting policy changes? (I) None material beyond the demerger discontinued-ops presentation. New markets/facilities/management? (F) New CEO/CFO; ongoing portfolio rotation; the focus is concentration (24 key markets, 30 Power Brands), not expansion.

APPENDIX B — Source Appendix — Unilever PLC (NYSE: UL)

Report date 2026-06-27. All sources accessed 2026-06-27. Primary sources prioritized; aggregated/third-party data labeled and reconciled to filings. UL is a UK foreign filer (20-F/6-K, reports EUR); there is no US 10-K/Form 4 corpus.

Company filings & primary disclosures

1. Unilever PLC — FY2025 Full Year Results (12-Feb-2026) — turnover €50,503m; USG +3.5% (vol +1.5/price +2.0); gross margin 46.9%; underlying operating margin 20.0%; underlying EPS €3.08; FCF; net debt €23.1bn; FY26 guidance. Source of record for segment turnover/margins/USG and underlying metrics.
2. Unilever PLC — Annual Report & Accounts 2025 — statutory financials, Directors’ Remuneration Report (PSP: underlying ROIC 30% / relative TSR 30% / USG 25% / SPI 15%), board/governance, segment detail.
3. Unilever Q1 / H1 / Q3 / Q4 2025 earnings-call transcripts (Q1 2025-04-24, H1 2025-07-31, Q3 2025-10-23, Q4 2026-02-12) — management framing of USG/volume/margin, Power-Brand growth, Wellbeing, GAP2030, FX, capital return.
4. SEC Form 425 / 6-K corpus (EDGAR CIK 0000217410) — Foods → McCormick business-combination communications (Form 425, filed 2026); director/officer change 6-Ks.
5. Unilever press release — “Unilever combines Unilever Foods with McCormick” (31-Mar-2026, unilever.com) and McCormick & Co IR release “McCormick to Combine with Unilever’s Foods Business” (ir.mccormick.com) — $44.8bn RMT terms ($15.7bn cash + ~$29.1bn stock; UL holders ~55.1%, UL retains ~9.9%; ~$600m synergies; ~$20bn combined revenue; close mid-2027; retained: Lipton RTD, Buavita, lifestyle nutrition, India/Portugal/Nepal foods).
6. Unilever Ice-Cream demerger materials — The Magnum Ice Cream Company N.V., admitted Euronext Amsterdam/LSE/NYSE 8-Dec-2025; 8-for-9 Unilever PLC share consolidation.
7. Unilever GAP / GAP2030 / Capital Markets Day (Nov-2024) materials and the Mar-2024 Productivity Programme announcement (~€800m savings / ~7,500 roles).
8. Unilever board / AGM disclosures — Nelson Peltz (Trian) NED appointment (20-Jul-2022), 2025 AGM re-election (98.03%); Chair Ian Meakins; CEO transition (Schumacher → Fernandez, 1-Mar-2025); 2020 NV/PLC unification.

Quantitative & market data

9. Aggregated fundamentals (multi-year income statement, balance sheet, cash flow, profitability/valuation ratios, enterprise value, per-share data) — third-party aggregated, reconciled to Unilever’s filings. FY25: rev €50,503m, GM 46.9%, op margin 20.0%, ROIC 14.3%, EV ~$146bn, EV/EBITDA 14.4x, net debt €22.3–23.1bn, goodwill €17,709m + intangibles €17,055m, shares 2,179m.
10. Public market & price data — 5-year ADR price history (current $60.55; 5-yr high $73.31 on 13-Feb-2026; 5-yr low $42.44 on 19-May-2022; year-end closes 2021–2025); own-history valuation percentiles (composite ~56th); recent news (Jun-2026: Thorne bid exploration, Accenture AI manufacturing partnership, Magnum tech roadmap).
11. Quantitative factor model (FactorsToday) — stock loadings, risk-adjusted leaderboard, idiosyncratic vol, related stocks. Beta 0.12; loadings UK +0.28 / LowVol +0.24 / Quality +0.14 / BetaFactor −0.46 / USDollar −0.29; 5-yr return +1.2%/yr (Sharpe −0.04); m3 +12.4% ann; RS_12m −9.3; related CCEP/PG/CL.

Peer & industry cross-reference

12. Peer FY2025 results / public multiples (June 2026) — P&G, Colgate, Nestlé, Reckitt, Beiersdorf, L’Oréal, Church & Dwight (EV/EBITDA, P/E, EV/sales, dividend yield), from each company’s own filings/results. Reckitt/Beiersdorf aggregator EV/EBITDA prints flagged as distorted; forward P/E used as the clean cross-check.
13. Trade press — Food Dive, FoodNavigator, FoodManufacture, Reuters, FT (Foods/McCormick combination, demerger, CEO change, Thorne bid exploration), accessed 2026-06-27.

Analytical frameworks

14. Greenwald & Kahn, “Competition Demystified” and Marathon / Chancellor, “Capital Returns” — moat taxonomy, ROIC/share-stability tests, capital-cycle / asset-growth lens.

All material numbers driving a verdict are reconciled to Unilever’s own filings, which are the primary source; aggregated/third-party data is used for acceleration and cross-check only.